RC
XENE icon

RBF Capital’s Xenon Pharmaceuticals XENE Stock Holding History

RBF Capital’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-15,000
Closed -$144K – 429
2018
Q2 		$144K Sell
15,000
-100
-0.7% -$621 0.02% 344
2018
Q1 		$73K Hold
15,100
– – 0.01% 359
2017
Q4 		$43K Buy
+15,100
New +$41K ﹤0.01% 368

Other funds holding XENE

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

RBF Capital's XENE Position: Q3 2018 in Review

RBF Capital sold out of Xenon Pharmaceuticals (XENE) in Q3 2018, closing a stake of 15,000 shares — an estimated $144K sold.

RBF Capital first reported a position in XENE in Q4 2017 and held it in 3 quarters. The position peaked at $144K in Q2 2018. 59 funds tracked by Wall St. Rank hold XENE as of Q3 2018.

  • RBF Capital reported no remaining Xenon Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • RBF Capital sold 15,000 Xenon Pharmaceuticals shares in Q3 2018, an estimated $144K.
  • RBF Capital first reported a position in Xenon Pharmaceuticals in Q4 2017 and held it in 3 quarters.
  • RBF Capital's Xenon Pharmaceuticals position peaked at $144K in Q2 2018.
  • 59 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q3 2018.

Based on RBF Capital's 13F filing for Q3 2018, filed 14 Nov 2018.